IMA Advisory Services’s Genmab GMAB Stock Holding History

IMA Advisory Services’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.13K	Buy	42 +1	+2%	+$30	﹤0.01%	758
2025 Q4	$1.26K	Buy	+41	New	+$1.28K	﹤0.01%	746

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

IMA Advisory Services's GMAB Position: Q1 2026 in Review

IMA Advisory Services increased its Genmab (GMAB) stake by 2.4% in Q1 2026, buying an estimated $30 and bringing the position to 42 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #758.

IMA Advisory Services first reported a position in GMAB in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.26K in Q4 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

IMA Advisory Services held 42 shares of Genmab worth $1.13K as of Q1 2026.
IMA Advisory Services bought 1 Genmab share in Q1 2026, an estimated $30.
Genmab made up ﹤0.01% of IMA Advisory Services's portfolio in Q1 2026, its #758 holding.
IMA Advisory Services first reported a position in Genmab in Q4 2025 and has held it in 2 quarters since.
IMA Advisory Services's Genmab position peaked at $1.26K in Q4 2025.
272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on IMA Advisory Services's 13F filing for Q1 2026, filed 6 May 2026.